Valuation: AstraZeneca PLC

Market Cap 267B 234B 216B 199B 378B 25,478B 384B 2,575B 1,011B 12,551B 1,003B 981B 43,148B P/E 2026 *
21.6x
P/E 2027 * 19x
Enterprise Value 286B 251B 231B 213B 405B 27,321B 412B 2,761B 1,084B 13,459B 1,076B 1,052B 46,269B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 4.18x
Free-Float
96.63%
Yield 2026 *
1.94%
Yield 2027 * 2.05%

Last Transcript: AstraZeneca PLC

Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-.--% - - 277B
-2.33%-2.09%+50.33%+162.29% 1,085B
-0.82%-2.30%+62.97%+61.11% 624B
-0.73%-4.98%+27.22%+84.46% 442B
+0.33%-1.17%+27.98%+26.90% 332B
-0.02%-2.85%+25.27%+44.88% 282B
+0.66%-1.42%-29.26%-39.30% 217B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 167B
-0.33%-0.62%-6.25%-32.26% 138B
Average -1.26%-1.95%+21.40%+49.03% 386.96B
Weighted average by Cap. -0.90%-2.23%+34.88%+81.61%

Financials

2026 *2027 *
Net sales 63.2B 55.28B 50.99B 47.1B 89.37B 6,028B 90.87B 609B 239B 2,970B 237B 232B 10,209B 66.77B 58.41B 53.87B 49.76B 94.41B 6,368B 96B 644B 253B 3,137B 251B 245B 10,785B
Net income 12.43B 10.87B 10.03B 9.26B 17.58B 1,186B 17.87B 120B 47.06B 584B 46.68B 45.66B 2,008B 13.94B 12.19B 11.24B 10.39B 19.71B 1,329B 20.04B 134B 52.76B 655B 52.33B 51.19B 2,251B
Net Debt 19.32B 16.9B 15.59B 14.4B 27.32B 1,843B 27.78B 186B 73.15B 908B 72.55B 70.97B 3,121B 11.85B 10.36B 9.56B 8.83B 16.75B 1,130B 17.03B 114B 44.84B 557B 44.48B 43.51B 1,913B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
172.23USD
Average target price
215.33USD
Spread / Average Target
+25.02%

Quarterly revenue - Rate of surprise